

Precision Study Underway – 100 Prostate Cancer Patients Treated in Just Three Radiation Sessions

Last week the Edinburgh Cancer Centre began treating prostate cancer patients within the framework of the so-called Precision Study. Patients receive only three radiation doses, with the Raypilot System used as a complement to ensure accurate motion control during treatment, thereby minimising potential side effects. The aim is to demonstrate that three sessions work as well as five in terms of both cancer eradication and the degree of side effects.

The Pace-B study*, published in 2024, showed that SBRT** with five radiation sessions is just as effective in curing cancer as traditional treatment involving 20–40 sessions. The Precision Study aims to further streamline treatment while reducing side effects and improving patient convenience. The treatments in the study are carried out using the Raypilot System, which enables real-time monitoring of organ movement. This system allows for urethra-sparing techniques and tighter radiation margins—factors that both improve targeting accuracy and reduce the risk of side effects.

Aiming for Improved Quality of Life

The study includes 100 patients across multiple clinics in Europe and the US and is led by Professor Duncan McLaren at the Edinburgh Cancer Centre in Scotland. His aim is to make prostate cancer treatment more comfortable for patients and improving their quality of life post-treatment.

"The goal of the Precision Study is to ensure that treatment with three radiation doses does not lead to greater side effects than those observed in the Pace-B study. I am confident that we can demonstrate effective cancer treatment with less side effects," says Professor McLaren.

A Collaborative Effort for Improved Healthcare

The study was initiated by researchers at various clinics using the Raypilot System.

"Our customers are interested in developing and improving healthcare, always with patient quality of life in focus. At the same time, healthcare providers across the Western world are striving to reduce treatment times and enhance both quality and efficiency. This study could contribute to such progress, benefiting all stakeholders—healthcare providers reduce costs while improving care, and patients gain a better quality of life," says Thomas Lindström, MD at Micropos Medical AB, the company behind the Raypilot System.

The first conclusions from the Precision Study are expected within one to two years, followed by a further five years of patient follow-up before final results can be presented.

* *Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer, van As et al, N Engl J Med 2024;391:1413-1425*

** *SBRT (Stereotactic Body Radiation Therapy) involves treatment in five or fewer sessions, over five or fewer consecutive days, with a significantly higher radiation dose per session compared to traditional treatment.*



Preparing for radiotherapy treatment in the Linear Accelerator Treatment Room: The Raypilot Receiver is securely positioned.

For further information, contact:

Thomas Lindström
Micropos Medical
thomas.lindstrom@micropos.se
+46 (0)31-760 80 05

Micropos Medical AB is a Swedish medical device company that develops, manufactures, and sells technology enabling enhanced radiotherapy cancer treatment. The Raypilot® System, the product from the company, generates high precision as well as high efficiency through real time tumour tracking in radiation treatment of prostate cancer. Using The Raypilot System, clinics can treat their patients with accuracy and reduced risk of damaging healthy tissue surrounding the tumour. The company is listed on the Spotlight Stock Market. www.micropos.se